Stock VIR VIR BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
10.39 USD +13.18% Intraday chart for Vir Biotechnology, Inc. +26.25% +3.28%
05-02 Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02 Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M
MT
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
BU
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
BU
Cytokinetics Appoints Sung Lee as CFO
MT
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024
CI
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024
CI
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
BU
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule
MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
BU
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
CI
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
AQ
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
BU
Vir Biotechnology's Q4 Loss Widens, Revenue Declines
MT
Vir Biotechnology, GSK Terminate Collaboration on Flu
DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VIR Stock
  4. News Vir Biotechnology, Inc.